Co-delivery of SIRT1 agonists with other small molecules that inhibit mitochondrial dysfunction, cardiac fibrosis, and parasite persistence will potentially form a complete therapeutic regimen against Chagas disease. This evidence concerns the gene SIRT1 and Chagas disease.